Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Atea Pharmaceuticals Inc
AVIRCurrent price
3.92 USD
+0.02 USD (+0.51%)
Last closed
3.9 USD
Company
ateapharma.com
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
300 676 480 USD
Yield for 12 month
+17.72 %
1Y
3Y
5Y
10Y
15Y
AVIR
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts. Address: 225 Franklin Street, Boston, MA, United States, 02110
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
2 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
+192 180 000 USD
Current Quarter
–
Last Quarter
–
Current Year
-416 000 USD
Last Year
-260 000 USD
Current Quarter
-104 000 USD
Last Quarter
-104 000 USD
Key Figures AVIR
1 year
3 years
5 years
10 years
EBITDA
-147 830 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-15.56 %
PEG Ratio
–
Return On Equity TTM
-29.16 %
Wall Street Target Price
2 USD
Revenue TTM
192 180 000 USD
Book Value
5.99 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
295.2 %
Dividend Yield
–
Gross Profit TTM
-81 936 000 USD
Earnings per share
-1.95 USD
Diluted Eps TTM
-1.95 USD
Most Recent Quarter
I 2024
Quarterly Earnings Growth YOY
264.1 %
Profit Margin
–
Dividend Analytics AVIR
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History AVIR
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation AVIR
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
58.974
Price Sales TTM
1.9026
Enterprise Value EBITDA
-260.4742
Price Book MRQ
0.5527
Financials AVIR
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators AVIR
For 52 weeks
2.77 USD
4.6 USD
50 Day MA
3.58 USD
Shares Short Prior Month
2 126 945
200 Day MA
3.57 USD
Short Ratio
7.64
Shares Short
2 243 492
Short Percent
3.74 %
BeatStart